Q32 Bio is developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
| Headquarters | Cambridge, MA |
| Website | www.q32bio.com |
| @Q32Bio | |
| Pipeline | Preclinical |
| Q32 Bio |